Randomized phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.
T. Mok
Consultant or Advisory Role - AVEO
Honoraria - AVEO
Research Funding - AVEO
E. Tan
No relevant relationships to disclose
K. Park
No relevant relationships to disclose
J. Jac
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
M. Han
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
F. C. Payumo
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
M. Credi
Stock Ownership - AVEO
K. McKee
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
M. M. Cotreau
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
P. Bhargava
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
W. Slichenmyer
Employment or Leadership Position - AVEO
Stock Ownership - AVEO